2 Drug Stocks Squeezing Shorts

BLUE and TXMD are signaling higher opens this morning

Jun 15, 2018 at 9:23 AM
facebook X logo linkedin

Shares of bluebird bio Inc (NASDAQ:BLUE) are up 0.5% in electronic trading, after the company reported positive early stage trial data for its LentiGlobin gene therapy in patients with sickle cell disease and thalassemia -- two blood disorders. Bluebird said it expects to submit a marketing application in the European Union (EU) later this year for LentiGlobin as a thalassemia treatment.

Looking at the charts, BLUE stock has been in a channel of higher highs and lows since bouncing off its 180-day moving average in early April -- and this rising trendline has continued to serve as support. And while the security remains off its mid-March record peak at $236.17, it's still maintaining a 10.6% year-to-date return, based on last night's close at $197.

Should the drug stock continue to climb, a continued round of short covering could create even bigger tailwinds. Although short interest is down 4.7% in the most recent reporting period, there are still 3.59 million BLUE shares sold short -- representing almost 8% of the security's float, or seven times the average daily pace of trading.

TherapeuticsMD Inc (NASDAQ:TXMD) stock is also signaling a positive open, up 5.1% ahead of the bell. J.P. Morgan Securities initiated coverage on the women's health specialist with an "overweight" rating and $11 price target -- a roughly 60% premium to last night's close at $6.88, and territory not charted since late 2015.

TXMD stock has been climbing up the charts since bottoming at a year-to-date low of $4.64 on March 27, gaining more than 48%. What's more, the shares topped out at an annual high of $7.66 one week ago today, and have since pulled back to support at their 20-day moving average.

Short sellers could help propel the security even higher. The 55.10 million TXMD shares currently sold short account for almost one-third of the stock's available float, or 20 days' worth of pent-up buying demand, at the average pace of trading.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI